Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered modelsCaroline M. Emery,Brian Corgiat,Justin Davis,David Sorrell, Mitch Johnson, Brent Kreider,Deborah KnoerzerCANCER RESEARCH(2022)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要